ACADIA PHARMACEUTICALS INC
Public company- Headquarters
- SAN DIEGO, California
- Ticker
- ACAD
- CIK
- 0001070494
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Executive Vice President, Head of Research and DevelopmentElizabeth H.Z. Thompson, Ph.D. | Oct 23, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Oruka Therapeutics, Inc.
Chief Commercial Officer appointed: Todd Edwards
- Executive departure
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of Research and Development of ACADIA PHARMACEUTICALS INC, retires the role, effective October 23, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 23, 2026Role: Executive Vice President, Head of Research and Development
Only one public record so far. We add events as soon as a new filing lands; watch ACADIA PHARMACEUTICALS INC to get them in your digest.
Last verified Nov 8, 2026